Compound Probiotic Ameliorates Acute Alcoholic Liver Disease in Mice by Modulating Gut Microbiota and Maintaining Intestinal Barrier
- PMID: 36456838
- DOI: 10.1007/s12602-022-10005-x
Compound Probiotic Ameliorates Acute Alcoholic Liver Disease in Mice by Modulating Gut Microbiota and Maintaining Intestinal Barrier
Abstract
Alcoholic liver disease (ALD) is a worldwide health threaten lack of effective treatment. Gut dysbiosis and concomitant augmented intestinal permeability are strongly implicated in the pathogenesis and progression of ALD. Research on the protective effect of probiotics on ALD is limited, and more effective intestinal microecological regulators and the related mechanisms still need to be further explored. In the present study, the protective effects and mechanisms of a compound probiotic against acute alcohol-induced liver injury in vivo were explod. It was showed that the compound probiotic ameliorated liver injury in acute ALD mice and stabilized the levels of ALT, AST, and TG in serum. The compound probiotic reversed acute alcohol-induced gut dysbiosis and maintained the intestinal barrier integrity by upregulating the production of mucus and the expression of tight junction (TJ) proteins and thus reduced LPS level in liver. Meanwhile, the compound probiotic reduced inflammation level by inhibiting TLR4/NF-κB signaling pathway and suppressed oxidative stress level in liver. Furthermore, the compound probiotic alleviated liver lipid accumulation by regulating fatty acid metabolism-associated genes and AMPK-PPARα signaling pathway. Noteworthy, fecal microbiota transplantation (FMT) realized comparable protective effect with that of compound probiotic. In conclusion, present study demonstrates the beneficial effects and underlying mechanism of the compound probiotic against acute alcohol-induced liver injury. It provides clues for development of novel strategy for treatment of ALD.
Keywords: Alcoholic liver disease; Compound probiotic; Fecal microbiota transplantation; Gut microbiota; Intestinal barrier; Lipopolysaccharide.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Fecal microbiota transplantation from Helicobacter pylori carriers following bismuth quadruple therapy exacerbates alcohol-related liver disease in mice via LPS-induced activation of hepatic TLR4/NF-κB/NLRP3 signaling.J Transl Med. 2025 Jun 3;23(1):627. doi: 10.1186/s12967-025-06573-5. J Transl Med. 2025. PMID: 40462165 Free PMC article.
-
New strain of Pediococcus pentosaceus alleviates ethanol-induced liver injury by modulating the gut microbiota and short-chain fatty acid metabolism.World J Gastroenterol. 2020 Oct 28;26(40):6224-6240. doi: 10.3748/wjg.v26.i40.6224. World J Gastroenterol. 2020. PMID: 33177795 Free PMC article.
-
Propionate Ameliorates Alcohol-Induced Liver Injury in Mice via the Gut-Liver Axis: Focus on the Improvement of Intestinal Permeability.J Agric Food Chem. 2022 May 25;70(20):6084-6096. doi: 10.1021/acs.jafc.2c00633. Epub 2022 May 12. J Agric Food Chem. 2022. PMID: 35549256
-
Microbiota, a key player in alcoholic liver disease.Clin Mol Hepatol. 2018 Jun;24(2):100-107. doi: 10.3350/cmh.2017.0067. Epub 2017 Dec 22. Clin Mol Hepatol. 2018. PMID: 29268595 Free PMC article. Review.
-
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.Crit Rev Food Sci Nutr. 2019;59(sup1):S116-S129. doi: 10.1080/10408398.2018.1544542. Epub 2018 Dec 22. Crit Rev Food Sci Nutr. 2019. PMID: 30580553 Review.
Cited by
-
Fecal microbiota transplantation from Helicobacter pylori carriers following bismuth quadruple therapy exacerbates alcohol-related liver disease in mice via LPS-induced activation of hepatic TLR4/NF-κB/NLRP3 signaling.J Transl Med. 2025 Jun 3;23(1):627. doi: 10.1186/s12967-025-06573-5. J Transl Med. 2025. PMID: 40462165 Free PMC article.
-
Clinical efficacy of probiotics in the treatment of alcoholic liver disease: a systematic review and meta-analysis.Front Cell Infect Microbiol. 2024 Mar 12;14:1358063. doi: 10.3389/fcimb.2024.1358063. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38533380 Free PMC article.
-
Gut Bacteria in Alcohol-Associated Liver Disease.Clin Liver Dis. 2024 Nov;28(4):663-679. doi: 10.1016/j.cld.2024.06.008. Epub 2024 Jul 24. Clin Liver Dis. 2024. PMID: 39362714 Review.
-
The development of probiotics and prebiotics therapy to ulcerative colitis: a therapy that has gained considerable momentum.Cell Commun Signal. 2024 May 14;22(1):268. doi: 10.1186/s12964-024-01611-z. Cell Commun Signal. 2024. PMID: 38745207 Free PMC article. Review.
-
Longitudinal Analysis of the Immunostimulatory Properties and Safety Profile of Lacticaseibacillus rhamnosus LRa05 as a Dietary Supplement.J Microbiol Biotechnol. 2025 Jul 14;35:e2502053. doi: 10.4014/jmb.2502.02053. J Microbiol Biotechnol. 2025. PMID: 40730491 Free PMC article.
References
-
- Zhou Y, Yuan G, Zhong F, He S (2022) Roles of the complement system in alcohol-induced liver disease. Clin Mol Hepatol 26(4):677–685. https://doi.org/10.3350/cmh.2020.0094 - DOI
-
- Soleimani V, Delghandi PS, Moallem SA, Karimi G (2019) Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review. Phytother Res 33(6):1627–1638. https://doi.org/10.1002/ptr.6361 - DOI
-
- Federico A, Dallio M, Loguercio C (2017) Silymarin/silybin and chronic liver disease: a marriage of many years. Molecules 22(2):191. https://doi.org/10.3390/molecules22020191 - DOI
-
- Gillessen A, Schmidt HH (2020) Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther 37(4):1279–1301. https://doi.org/10.1007/s12325-020-01251-y - DOI
-
- Chi X, Pan CQ, Liu S, Cheng D, Cao Z, Xing H (2020) Regulating intestinal microbiota in the prevention and treatment of alcohol-related liver disease. Can J Gastroenterol Hepatol 2020:6629196. https://doi.org/10.1155/2020/6629196 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous